Clinical evidence tools built around US workflows often prioritize FDA materials. European healthcare professionals also need the product information approved for their own jurisdiction. For centrally authorized medicines, the European Medicines Agency publishes that information on the medicine page in a document that includes the Summary of Product Characteristics, or SmPC.
The difference is not cosmetic. Authorized indications, age groups, contraindications, warnings, and conditions of use can differ between jurisdictions. A European evidence review should therefore make the applicable European source easy to identify.
What the SmPC contains
The EMA describes the SmPC as the basis of information for healthcare professionals on how to use a medicine safely and effectively. It covers the approved conditions of use, including indications, posology, contraindications, warnings, interactions, pregnancy and lactation, undesirable effects, and pharmacological properties.
SmPCs are kept updated during the lifecycle of a medicine as efficacy and safety information changes. They do not replace independent comparative research, but they are authoritative for questions about the approved European product information.
How CliniAtlas uses EMA sources today
CliniAtlas uses a curated EMA medicine registry to route relevant regulatory questions and return official EPAR and product-information links alongside literature results. The current prototype does not claim to maintain a complete full-text index of every SmPC.
This narrower approach is intentional and inspectable: identify the relevant European medicine record, show the official source, and let the reader open the current regulator-published document. Future structured ingestion can expand coverage without pretending that a partial registry is already comprehensive.